Literature DB >> 2149018

Diagnostic and treatment procedures induced by cervical cancer screening.

M van Ballegooijen1, M A Koopmanschap, G J van Oortmarssen, J D Habbema, K T Lubbe, H M van Agt.   

Abstract

The amount of diagnostic and treatment procedures induced by cervical cancer screening has been assessed prospectively and related to mortality reduction. Assumptions are based on data from Dutch screening programmes and on a scenario for future developments. With 5 invitations for screening, between ages 37-70 every eight years, 13 deaths are avoided per million women per screening year. Each death avoided is balanced by 2800 preventive smears, 9 women referred to a gynaecology department and 4 minor treatment procedures (conserving treatment or exconisation). 25 invitations in a life-time avoids 27 deaths per million women per screening year but with 7300 preventive smears, 22 referrals and 8 small treatment procedures. Thus intensifying screening will not only result in diminishing returns of extra screening efforts, but also in increasing risk for women to undergo unnecessary (no invasive disease or death avoided) diagnostic and treatment procedures. The balance between beneficial and adverse effects deteriorates strongly when hysterectomies play an important part in the management of cervical intraepithelial neoplasia.

Entities:  

Mesh:

Year:  1990        PMID: 2149018     DOI: 10.1016/0277-5379(90)90615-z

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  3 in total

1.  Predicting mortality from cervical cancer after negative smear test results.

Authors:  G J van Oortmarssen; J D Habbema; M van Ballegooijen
Journal:  BMJ       Date:  1992-08-22

2.  Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer.

Authors:  G J van Oortmarssen; J D Habbema
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

3.  Preventive Pap-smears: balancing costs, risks and benefits.

Authors:  M van Ballegooijen; J D Habbema; G J van Oortmarssen; M A Koopmanschap; J T Lubbe; H M van Agt
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.